Abstract-Angiotensin (Ang) II induces hypertension by mechanisms mediated in part by adaptive immunity and T effector lymphocytes. T regulatory lymphocytes (Tregs) suppress T effector lymphocytes. We questioned whether Treg adoptive transfer would blunt Ang II-induced hypertension and vascular injury. Ten-to 12-week-old male C57BL/6 mice were injected IV with 3ϫ10 5 Treg (CD4 ϩ CD25 ϩ ) or T effector (CD4 ϩ CD25 Ϫ ) cells, 3 times at 2-week intervals, and then infused or not with Ang II (1 g/kg per minute, SC) for 14 days. Ang II increased systolic blood pressure by 43 mm Hg (PϽ0.05), NADPH oxidase activity 1.5-fold in aorta and 1.8-fold in the heart (PϽ0.05), impaired acetylcholine vasodilatory responses by 70% compared with control (PϽ0.05), and increased vascular stiffness (PϽ0.001), mesenteric artery vascular cell adhesion molecule expression (2-fold; PϽ0.05), and aortic macrophage and T-cell infiltration (PϽ0.001). All of the above were prevented by Treg but not T effector adoptive transfer. Ang II caused a 43% decrease in 
A ngiotensin (Ang) II plays a role in the development of hypertension in part through vasoconstriction and increased peripheral vascular resistance, endothelial dysfunction, structural vascular remodeling, and low-grade inflammation. 1 Ang II plays a key role in inflammation, through oxidative stress and production of adhesion molecules and cytokines. 2, 3 Innate and adaptive immunity are involved in Ang II-induced hypertension and end-organ damage, [3] [4] [5] [6] as first suggested by Shao et al, 7 who demonstrated that Ang II infusion in rats caused recruitment of T cells in the kidney, an effect prevented by Ang II type 1 receptor (AT 1 R) blockers. Guzik et al 8 showed that Ang II-induced increase in blood pressure (BP), endothelial dysfunction, vascular remodeling, and superoxide production were reduced in rag-1 Ϫ/Ϫ mice deficient in T and B cells and could be restored by adoptive transfer of T but not B cells.
Mouse T and B cells and macrophages isolated from the spleen express AT 1a R and, in vitro, Ang II regulates the proliferation of wild-type but not AT 1a R-deficient (agt1ar Ϫ/Ϫ ) splenic lymphocytes. 9 Angiotensinogen, Ang I, and Ang II induced proliferation of human T and natural killer cells, 10 suggesting a functional renin-Ang system in these cells. These cells express renin, renin receptors, angiotensinogen, Angconverting enzyme, AT 1 R, and Ang II type 2 receptor. Similarly, mouse T lymphocytes express a local renin-Ang system regulating T-cell activation, expression of tissue homing markers, and production of tumor necrosis factor (TNF) ␣. 11 A subset of T lymphocytes, regulatory T lymphocytes (Tregs), suppresses innate and adaptive immune responses, 12 including proinflammatory effects of other lymphocytes, macrophages, dendritic cells, and neutrophils. They express CD4, interleukin (IL) 2 receptor ␣-subunit (CD25), and the transcription factor X-linked forkhead/winged helix (Foxp3). 13 Deficiency in Treg is associated with autoimmune diseases in humans and mice. 14 Treg lymphocytes of patients with type 1 diabetes mellitus had reduced capacity to suppress T-cell proliferation in vitro. 15 The number and suppressor function of Treg were decreased in apolipoprotein E knockout (apoE Ϫ/Ϫ ) mice, 16 and Treg adoptive transfer attenuated development of atherosclerosis in these mice. Recently, we showed chromosome 2-dependent modulation of immune responses in genetic hypertension via Treg lymphocytes. 17 In the Dahl salt-sensitive (SS) rats, vascular inflammation and BP elevation were associated with dysfunction of Treg suppressor effects. Consomic SSBN2 rats, which have the SS rat genome and chromosome 2 from normotensive Brown Norway rats, had improved Treg function and decreased hypertension and vascular and systemic inflammatory mediators compared with SS rats. Furthermore, adoptive transfer of Treg prevented Ang II-induced cardiac hypertrophy and fibrosis, TNF-␣ expression, immune cell infiltration, and electric remodeling of the heart independent of BP-lowering effects. 18 To test the hypothesis that enhancing Treg-mediated immune suppression will blunt Ang II-induced hypertension and vascular injury, we determined whether Treg adoptive transfer prevents Ang II-induced hypertension, endothelial dysfunction, vascular remodeling, oxidative stress, and inflammation in mice.
Methods

Animals
The study was approved by the Animal Care Committee of the Lady Davis Institute and McGill University, and followed recommendations of the Canadian Council of Animal Care. Treg adoptive transfer was performed as described previously with minor modifications. 19 Ten-to 12-week-old male C57BL/6 mice (Harlan Laboratories, Indianapolis, IN) were injected IV via the tail vein 3 times, at 2-week intervals, with PBS, 3ϫ10 5 CD4
, and then infused with Ang II (1 g/kg per minute, SC) for 14 days using ALZET osmotic minipumps (Durect). Control mice were similarly injected IV with vehicle (PBS). Systolic BP (SBP) was measured during Ang II infusion 3 times per week by the tail-cuff method using a MC4000 BP analysis system (Hatteras Instruments). After 2 weeks of treatment, mice were killed under anesthesia with isoflurane. BP was also determined by telemetry in a separate group of mice. Ten-week-old male mice were anesthetized with isoflurane, surgically instrumented with PA-C10 radiotelemetry transmitters as recommended by the manufacturer (Data Sciences International), allowed to recover for 7 days, and treated as described above, and then BP was determined every 5 minutes for 10 seconds for 2 consecutive days. Thereafter, mice were infused or not with Ang II for 14 days, and BP was determined throughout this period.
Isolation and Adoptive Transfer of Treg and CD4
؉
CD25
؊ Cells T lymphocytes were isolated from 3 spleens of 10-to 12-week-old male C57BL/6 mice through CD4 ϩ T-cell-negative selection followed by CD25 ϩ T-cell-positive selection of splenocytes as per the manufacturer's instructions using the EasySep Mouse CD4 ϩ T Cell Pre-Enrichment and CD25 Positive Selection kits (Stem Cell Technologies). Purity of Treg cells was verified by flow cytometry by first blocking with Fc-Block (BD Biosciences) for 30 minutes at 4°C, followed by staining with anti-CD4 APC-conjugated (RM4-5) and anti-CD25 PE-conjugated (3C7) antibodies (BD Biosciences) for 1 hour at 4°C. Cells were washed, resuspended, and analyzed using FACSCalibur flow cytometer (BD Bioscience) and FCS Express V3 software (De Novo Software). To perform adoptive transfer, mice were placed under a heat lamp to increase blood flow to the tail vein and then transferred to a holding device (AIMS restrainer). The lateral tail veins were identified and 100 L of PBS or 3ϫ10 5 cells injected using a 0.5-mL syringe with a 26-gauge needle.
Endothelial Function and Vessel Mechanics
Second-order branches of mesenteric arteries (ID 150 to 250 m) were dissected and mounted on a pressurized myograph, and endothelial function and vessel mechanics were determined as described previously. 20 
Data Analysis
Results are presented as meanϮSEM. Comparisons between multiple groups were done by 1-way ANOVA. Comparison of SBP was by 2-way ANOVA for repeated measurements. Acetylcholine response curves and stress/strain relationships were compared by 2-way ANOVA on the sum of squares from each curve. For plasma cytokines, control and TregϩAng II groups were jointly considered as controls. Aortic and renal cortex Foxp3 and monocyte/macrophage specific antigen-2 (MOMA-2) immunofluorescence were compared using Kruskal-Wallis 1-way ANOVA. ANOVA was followed in all of the cases by Student-Newman-Keuls or Bonferroni post hoc tests. PϽ0.05 was considered statistically significant.
Results
Adoptive Transfer of Treg Prevents Ang II-Induced Hypertension
Mice were treated with 3 adoptive transfers of Treg at 2-week intervals, starting 4 weeks before infusion of Ang II. Cell purity determined by flow cytometry indicated that Treg and Teff preparations contained 81.1Ϯ2.5% and 5.5Ϯ1.2% of CD4 ϩ
CD25
ϩ cells, respectively. To test the specificity of Treg effects, a group of mice received 3 adoptive transfers of Teff.
Ang II induced a progressive increase of SBP ( Figure 1A ), which was prevented by adoptive transfer of Treg but not Teff. Results with the tail-cuff technique were confirmed by telemetry ( Figure 1B and 1C) . Body weight and heart weight:tibia length ratio were not affected by any treatment (data not shown).
Adoptive Transfer of Treg Prevents Ang II-Induced Impairment of Mesenteric Artery Endothelium-Dependent Relaxation
Ang II treatment impaired the vasodilatory response of mesenteric arteries to acetylcholine, and this was prevented by adoptive transfer of Treg and slightly reduced by Teff (Figure 2A and 2C). Vasodilatory responses to acetylcholine were abrogated by the NO synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME) in control and TregϩAng II groups, but no significant change was noted in the PBSϩAng II and TeffϩAng II groups ( Figure 2B and 2C), indicating that endothelial NO synthase-dependent vasodilatory responses were impaired by Ang II and that this was not corrected by Teff transfer. Vasodilation with sodium nitroprusside was similar in all of the groups ( Figure 2D ).
Adoptive Transfer of Treg Prevents Ang II-Induced Mesenteric Artery Stiffness
No significant changes in media:lumen ratio or media crosssectional area of resistance mesenteric arteries were observed (Table S1 , available in the online Data Supplement). However, Ang II infusion resulted in displacement to the left of stress/ 
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strain curves of Ang II-infused mice, indicating increased stiffness compared with arteries from control mice ( Figure 3 and Table S1 ), effect abolished by administration of Treg but not Teff.
Adoptive Transfer of Treg Prevents Ang II-Induced Oxidative Stress
Ang II infusion increased NADPH oxidase activity in both the aorta and the heart ( Figure 4A and 4B). Adoptive transfer of Treg but not Teff prevented this effect. Ang II infusion increased superoxide-induced dihydroethidium fluorescence in the aorta, which was abrogated by adoptive transfer of Treg but not Teff ( Figure 4C ).
Adoptive Transfer of Treg Prevents Ang II-Induced Immune Response
Plasma levels of the proinflammatory cytokines interferon (IFN)-␥, TNF-␣, and IL-6 were increased by Ang II, which was prevented by Treg adoptive transfer but unaffected by Teff transfer ( Figure 5 ). Plasma levels of the anti-inflammatory cytokine IL-10 were significantly increased by Ang II treatment and prevented by Treg transfer but not affected by Teff ( Figure  5 ). Ang II treatment increased the levels of vascular cell adhesion molecule 1 in mesenteric arteries, which was prevented by adoptive transfer of Treg but not Teff ( Figure 6A ). Monocyte/ macrophage-specific antigen MOMA-2 immunostaining was increased in aortic adventitia and periadventitial fat by Ang II in mice treated with vehicle or Teff, whereas no change was observed in mice that received Treg ( Figure 6B ). In addition, Ang II treatment increased T-cell infiltration in the aortic adventitia and periadventitial fat, an effect prevented by Treg but not by Teff ( Figure 6C ).
Renal Cortex, Site of Treg Action?
Expression of Foxp3, a marker of Treg, was examined by immunofluorescence in aorta. A very low number of Foxp3 ϩ cells was associated with a 9-fold increase in monocyte/macrophages in the renal cortex as revealed by MOMA-2 staining ( Figure  7C ). Treg transfer did not reduce MOMA-2 staining. However, Teff adoptive transfer increased monocyte/macrophage infiltration in the renal cortex 1.6-fold further.
Discussion
Multiple lines of evidence link cardiovascular disease, including hypertension, with a chronic low-grade inflammatory state. More recently, innate and adaptive immunity have been identified as playing a role in cardiovascular disease and hypertension. 4 -6 The findings of the present study support and extend this concept by demonstrating that Tregs are involved in the pathophysiology of Ang II-induced BP elevation and vascular injury.
The observation that Treg adoptive transfer prevented Ang II-induced hypertension, vascular damage, and immune cell infiltration complements and extends the understanding of a role of T effector lymphocytes in hypertension provided by the study of Ang II effects in rag-1 Ϫ/Ϫ mice lacking T and B cells 8 and that Treg adoptive transfer prevents cardiac hypertrophy, inflammation, and electric remodeling induced by Ang II. 18 Tregs have been characterized as potent suppressors of T-helper lymphocytes, but molecular mechanisms through which they exert their suppressive effects remain unknown. 21 The suppressive action of Treg is also exerted on other cells, such as activated monocytes and macrophages. 12 Accordingly, the results of the present study suggest that not only adaptive but also innate immune responses were prevented by adoptive transfer of Tregs, because macrophage infiltration was decreased in adventitia and periadventitial fat. It is noteworthy that we observed previously that Ang II-induced hypertension and vascular damage were blunted in mcsf Op/Op mice deficient in macrophages and innate immunity. 22 Ang II-induced hypertension and vascular damage are mediated at least partly through production of oxidative stress by macrophages and T lymphocytes. Both cell types express AT 1 R and NADPH oxidase. 9,11,23, 24 Guzik et al 8 demonstrated that adoptive transfer of T cells deficient in AT 1 R (at1ar Ϫ/Ϫ ) or lacking a functional NADPH oxidase (T cells from p47 phoxϪ/Ϫ mice) into rag-1 Ϫ/Ϫ mice impaired the ability of Ang II to induce BP elevation and vascular damage. Decreased oxidative stress in vascular tissues of mice receiving Treg was associated with suppression of both macrophages and T lymphocytes, both of which could have contributed to Ang II-induced oxidative stress. Whether reactive oxygen species produced by macrophages and T lymphocytes infiltrating the adventitia and periadventitial fat are able to reach and react with endothelium-derived NO, contributing to endothelial dysfunction, 25 remains to be determined.
Increased arterial stiffness is part of Ang II-induced vascular damage in both rodents 26 and humans 27 and is 
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associated with low-grade inflammation. 28 Here we show that a strategy modulating immune homeostasis interferes with Ang II-induced vascular stiffness that contributes to the pathophysiology of hypertension. Kvakan et al 18 demonstrated that transfer of Treg interfered with Ang II-induced inflammatory and immune responses and ameliorated cardiac hypertrophy and fibrosis, TNF-␣ expression, immune cell infiltration, and electric remodeling. However, Treg had no effect on Ang II-induced BP elevation. This discrepancy with our study may be explained by differences in Treg adoptive transfer protocol and mouse strain. Here, mice were injected IV 3 times, at 2-week intervals, with 3ϫ10 5 Treg cells, and then infused with Ang II for 14 days, whereas, in the study of Kvakan et al, 18 mice were injected IV only once with 2ϫ10 5 Treg, 1 day after the beginning of the Ang II infusion. Repeated injection with 50% more Treg as in our study may be more effective. The preventive strategy used in the present study versus the "treatment" strategy in the study of Kvakan et al 18 may also explain different effects on BP. Finally, Kvakan et al 18 used NMRI mice, whereas we studied C57BL/6 mice. NMRI mice are prone to develop glomerulonephritis with aging (www. criver.com) and have 2 renin genes, whereas C57BL/6 mice have 1 renin gene. 29 Other factors, including differences in handling of mice, differential feeding, and intestinal microbiota, may contribute to modulate the immune responses and their effects on the vasculature and BP to explain the different behavior of mice in 2 experimental settings.
We demonstrated previously that genetic background provides a framework linking the genome, inflammation, immunity, and a role of Treg in salt-sensitive hypertension. 17 In consomic SSBN2 rats bearing a chromosome 2 from normotensive Brown-Norway rats on a Dahl SS genetic background, both BP and vascular inflammation were reduced, associated with enhanced Treg activity in the aortic wall, as demonstrated by increased expression of Foxp3 and the anti-inflammatory cytokines transforming growth factor ␤ and IL-10. The present study extends this concept, showing that manipulation of the Treg pool can prevent Ang IIinduced hypertension, inflammation, and immune response.
Ang II-induced hypertension, vascular damage, and immune cell infiltration were associated with increased plasma inflammatory cytokines IFN-␥, TNF-␣, and IL-6. Somewhat surprisingly, IL-10 levels increased with Ang II infusion and decreased with Treg adoptive transfer but not with Teff transfer. In basal conditions the production of IL-10 may be sufficient to moderate the expression of inflammatory cytokines. An increase in systemic IL-10 in association with enhanced levels of inflammatory cytokines has been observed in patients with heart failure after acute myocardial infarction 30 and in dilated cardiomyopathy. 31 Interestingly, Treg adoptive transfer was associated with normalization of plasma levels of inflammatory cytokines and of IL-10, as well as the suppression of macrophage and T-lymphocyte infiltration. This may be interpreted as a result of feedback loops that modulate proinflammatory cytokines by increases in anti-inflammatory IL-10 acting in a counterregulatory fashion. This may apply to systemic levels of cytokines, because local levels may change in a different way, with enhanced IL-10 associated with increased Treg vascular infiltration as found in consomic SSBN2 rats, compared with increased IFN-␥, TNF-␣, and IL-6 with Teff infiltration in the vasculature in Dahl SS rats. 17 The kidney plays a major role in long-term control of BP and in the development and maintenance of hypertension. 32 Ang II-induced hypertension was associated with a decrease in Treg and an increase in monocyte/macrophages in the renal cortex. Treg adoptive transfer was accompanied by increased Treg in the renal cortex. Although this did not result in a significant decrease in monocyte/macrophage infiltration, this may have reduced inflammation, renal damage, and BP rise. The kidney may represent one of the sites of action of Treg that could play an important role in the regulation of inflammation-induced BP rise. It was not possible to detect changes in Treg in the aorta in this study, which might be because of the technique used. Further experiments will be necessary to better understand the direct effects of Treg on the vasculature.
A limitation to the present study is the fact that mechanisms whereby Treg may improve vascular effects and BP in Ang II-infused mice were not completely elucidated. IL-10 -mediated effects could play a role via anti-inflammatory actions, but this needs to be further investigated. Further studies, particularly in humans, will be necessary to establish that immune imbalance plays a role in hypertension in humans as in Ang II-dependent hypertension in mice. Finally, whether effects on endothelial function, oxidative stress, and plasma cytokines caused BP rise or are secondary to hypertension remains to be determined.
Perspectives
The present study demonstrates that anti-inflammatory Treg lymphocytes modulate Ang II-induced BP elevation, vascular oxidative stress, inflammation, and endothelial dysfunction, extending previous findings of other investigators on effects of Treg on Ang II effects on the heart. T-regulatory lymphocytes seem to be implicated in mechanisms that modulate the degree to which Ang II may induce hypertension, vascular injury, and an inflammatory response. Together with previous studies on T effector cells, particularly Th1 and Th17, and their role in BP elevation and vascular damage, this suggests that a ying/yang 
Expanded Methods
Endothelial function and vessel mechanics
Second-order branches of the mesenteric arterial tree (internal diameter between 150-250µm) were dissected and mounted on a pressurized myograph as previously described. 1 Briefly, vessels were equilibrated for 60 min at 45mmHg intraluminal pressure in warmed oxygenated (95% air-5% CO 2 ) Krebs solution (pH 7.4) containing (mmol/l): 120 NaCl, 25 NaHCO 3 , 4.7 KCl, 1.18 KH 2 PO 4 , 1.18 MgSO 4 , 2.5 CaCl 2 , 0.026 EDTA and 5.5 glucose. Media and lumen diameters were measured by a computer-based video imaging system (Living Systems Instrumentation, Burlington, Virginia, USA). Endothelium-dependent and -independent relaxation was assessed by measuring the dilatory responses to cumulative doses of acetylcholine (Ach, 10 -9 to 10 -4 mol/L) or sodium nitroprusside (SNP, 10 -8 to 10 -4 mol/L), respectively, in vessels precontracted with norepinephrine (NE, 5 x 10 -5 mol/L). To evaluate the contribution of nitric oxide (NO) to the vascular response, the dose-response curve to Ach was determined before and after a 30-minute preincubation with the NO synthase inhibitor N ω -nitro-L-arginine methyl ester (L-NAME, 10 -4 mol/L). Thereafter, vessels were perfused with Ca
2+
-free Krebs solution containing 10 mmol/l EGTA for 30 min to eliminate vascular tone. Media and lumen diameter were measured at 3, 10, 20, 30, 40, 45, 60, 80, 100, 120 and 140 mmHg intraluminal pressures. Media cross-sectional area, media/lumen ratio, and stress and strain were calculated as previously described. 
Reduced nicotinamide adenine dinucleotide (NADPH) oxidase activity and generation of reactive oxygen species (ROS)
ROS generation was determined in aorta and apex of the heart by measuring NADPH oxidase activity by chemiluminescence using lucigenin and NADPH, as described in our previous studies. 3 Vascular superoxide (•O 2 ‾) production was assessed on 5 µm cryosections of aorta with the superoxide-sensitive fluorescent dye dihydroethidium (DHE, 2 µmol/L) in dark conditions for 5 min at 37°C. Fluorescence was visualized and captured with a fluorescence microscope with a CY3 filter as previously described. 
Plasma cytokine measurement
Plasma levels of interleukin (IL)-6, IL-10, interferon (IFN)-γ , and tumor necrosis factor (TNF)-α were measured with a Bio-Rad Laboratories Bio-Plex Multiplex System (Hercules, CA, USA) by an operator unaware of the groups studied.
Western blot analysis
Protein expression was determined by Western blot 4 using specific antibody antivascular cell adhesion molecule (VCAM)-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Signal was revealed by chemiluminescence (SuperSignal West Pico, Thermo Scientific, Rockford, IL, USA) with the Molecular Imager Chemidoc XRS system (BioRad, Mississauga, ON, Canada), and quantified by densitometry using Image lab software (Bio-Rad). Membranes were subsequently stripped and reprobed with anti-ß- 
